Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mannkind Corp (NQ: MNKD )

6.540 +0.060 (+0.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mannkind Corp

< Previous 1 2 Next >
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent
From MannKind
Via GlobeNewswire
MannKind Corporation Announces Participation at Upcoming Conferences
From MannKind
Via GlobeNewswire
MannKind Corporation Reports 2023 Second Quarter Financial Results
From MannKind
Via GlobeNewswire
MannKind Corporation Announces Participation in the 2023 Wedbush PacGrow Healthcare Conference
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2023 Second Quarter Financial Results Conference Call on August 7, 2023
From MannKind
Via GlobeNewswire
MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)
From MannKind
Via GlobeNewswire
Dr. Burkhard Blank Joins MannKind as Executive Vice President of Research & Development and Chief Medical Officer
From MannKind
Via GlobeNewswire
MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference
From MannKind
Via GlobeNewswire
CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial Results
Conference Call to Begin Today at 5:00 p.m. (ET) 
From MannKind
Via GlobeNewswire
Mannkind Corporation Reports 2023 First Quarter Financial Results
Conference Call to Begin Today at 5:00 p.m. (ET) 
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023
From MannKind
Via GlobeNewswire
Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer
From MannKind
Via GlobeNewswire
MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference
From MannKind
Via GlobeNewswire
MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results
Conference Call to Begin Today at 5:00 p.m. (ET) 
From MannKind
Via GlobeNewswire
MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023
From MannKind
Via GlobeNewswire
Mannkind Corporation to Participate in the SVB Securities Global Biopharma Conference
From MannKind
Via GlobeNewswire
MannKind Corporation to Participate in the Lytham Partners Investor Select Conference
From MannKind
Via GlobeNewswire
MannKind’s Inhaled Clofazimine Will Advance to an Adaptive Phase 2/3 Study For Potential Treatment of Rare Lung Disease
From MannKind
Via GlobeNewswire
MannKind Corporation to Present at 2023 Annual J.P. Morgan Healthcare Conference
From MannKind
Via GlobeNewswire
MannKind to Present Two Posters at 22nd Annual Diabetes Technology Meeting
From MannKind
Via GlobeNewswire
MannKind Corporation Reports 2022 Third Quarter Financial Results
Conference Call to Begin Today at 9:00 a.m. (ET) 
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2022 Third Quarter Financial Results Conference Call on November 8, 2022
From MannKind
Via GlobeNewswire
Global Brain Tumor Diagnosis & Treatment Market Could Exceed $880 Million By 2027
Via FinancialNewsMedia
The Autism Spectrum Disorders (ASD) Market Is Projected To Reach $4.53 Billion By 2026
Via FinancialNewsMedia
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.